InVivo Therapeutics® Corporation
Name
85822414-MIT.pdf
Description
Full printable version
Size
5.89 MB
Format
Adobe PDF
Checksum (MD5)
0c37f320f79a41beabe83937b9e83819
Author(s)
Reynolds, Francis M., M.B.A. Massachusetts Institute of Technology
Advisor(s)
Arnoldo Hax.
Date Issued
2006
Publisher
Massachusetts Institute of Technology
Abstract
To date, the primary treatment for spinal cord injuries has been the use of spinal fixation devices to create a stable environment for the spinal cord to heal. The second treatment option is to remove soft tissue near and around the spinal cord intended to reduce pressure on the spinal cord and allow the spinal cord to heal on its own. InVivo Therapeutics Corporation is a startup founded to commercialize novel science and technology that was developed through a collaborative effort between the Massachusetts Institute of Technology's Langer labs, and the department of Neuroscience at Harvard Medical School. Together they have created a patent pending medical device that will provide the first "Neuro-Tissue Engineered" implantable device for the immediate treatment of spinal cord injuries. We expect to have our first product on the market in 2010, and we will continue to work in our labs to develop a portfolio of three to four product categories in order to meet the systemic needs of the spinal cord injury patient. This thesis presents the first business plan, to commercialize this innovative treatment option.
(cont.) It is always challenging to be first to market with such an innovative product, so we have meticulously explored all relevant strategic initiatives, and tactical tasks required to bring our products to market. As the result we have developed a comprehensive business plan to ensure InVivo's success. Key components of the plan are: Introduction to InVivo Therapeutics, InVivo's business model, critical strategic analysis, functional strategies, financial analysis, and an integrative strategic framework. We have created a vision, mission, and strategic model that will lead to InVivo Therapeutics becoming a global leader in the treatment of neurological disease.
Description
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management, 2006.
Includes bibliographical references (leaf 100).
Subjects
Sloan School of Management.
MIT Department
Sloan School of Management
Terms of Use
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Persistent DSpace Link
